Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2010

01-11-2010 | Head and Neck Oncology

Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer

Authors: Jen-Tsun Lin, MD, Mu-Kuan Chen, MD, PhD, Kun-Tu Yeh, MD, Cheng-Shyong Chang, MD, Tung-Hao Chang, MD, Chi-Yon Lin, MS, Yi-Chuan Wu, MS, Bi-Wen Su, MS, Kuan-Der Lee, MD, PhD, Pey-Jium Chang, PhD

Published in: Annals of Surgical Oncology | Issue 11/2010

Login to get access

Abstract

Background

The aim of this study was to evaluate the prognostic value of the Jagged-1/Notch-1 expression in patients with head and neck carcinoma and to examine the possible role of the Jagged-1/Notch-1 signaling in tumorigenesis.

Methods

Immunohistochemical staining was performed on 59 formalin-fixed, paraffin-embedded head and neck carcinoma surgical specimens for Jagged-1 and Notch-1 expression. The head and neck cancer cell line, Fadu, with or without ectopic expression of the intracellular domain of Notch-1 (NICD) was also used for examining the tumorigenic capacity in vitro and in vivo.

Results

The study included 59 patients with a median age of 54 years (range, 35–73 years). Patients harboring tumors with both high-level Jagged-1 (J1Hi) and high-level Notch-1 (N1Hi) had a worse overall survival than the patients only with J1Hi or N1Hi as well as the patients with low-level Jagged-1 and Notch-1 (J1Lo/N1Lo) (P < 0.001). The 5-year survival rate and the median survival time were 5% and 10.9 months for J1Hi/N1Hi patients, while they were 35.04% and 47.7 months for non-J1Hi/NiHi patients. Ectopic expression of the active Notch-1 (NICD) in Fadu cells greatly enhanced cell migration and invasiveness in vitro and tumorigenic capacity in vivo.

Conclusions

High-level coexpression of Jagged-1 and Notch-1 is associated with poor overall survival in patients with head and neck cancer. Constitutive activation of the Notch signaling, which is possibly initiated by the direct interaction between Jagged-1 and Notch-1 in head and neck cancer, confers tumor cells with a more aggressive phenotype.
Literature
1.
Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223–33.CrossRefPubMed
2.
3.
Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756–67.CrossRefPubMed
4.
Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserve domains to powerful functions. Curr Top Microbiol Immunol. 1998;228:273–324.PubMed
5.
Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(Suppl 1):59–72.CrossRefPubMed
6.
Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6:R605–15.CrossRefPubMed
7.
8.
Miele L, Miao H, Nickoloff BH. Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6:313–23.CrossRefPubMed
9.
Wang Z, Banerjee S, Li Y, et al. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778–84.CrossRefPubMed
10.
Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483–93.CrossRefPubMed
11.
Dickson BC, Mulligan AM, Zhang H, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20:685–93.CrossRefPubMed
12.
Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64:6854–7.CrossRefPubMed
13.
Mungamuri K, Yang X, Thor AD, et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.CrossRefPubMed
14.
Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol. 2007;27:705–10.CrossRef
15.
Osipo C, Golde TE, Osborne BA, et al. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest. 2008;88:11–7.CrossRefPubMed
16.
Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.CrossRefPubMed
17.
Zavadil J, Cermak L, Soto-Nieves N, et al. Integration of TGF-β/Smad and Jagged1/Notch signaling in epithelial-to-mesenchymal transition. EMBO J. 2004;23:1155–65.CrossRefPubMed
18.
Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 2008;105:6392–7.CrossRefPubMed
19.
20.
Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18:5973–81.CrossRefPubMed
21.
Kiaris H, Politi K, Grimm LM, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165:695–705.PubMed
22.
Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001;42:467–72.CrossRefPubMed
23.
Ascano JM, Beverly LJ, Capobianco AJ. The C terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem. 2003;278:8771–9.CrossRefPubMed
24.
Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMed
25.
Zeng QH, Li SG, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8:13–23.CrossRefPubMed
Metadata
Title
Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer
Authors
Jen-Tsun Lin, MD
Mu-Kuan Chen, MD, PhD
Kun-Tu Yeh, MD
Cheng-Shyong Chang, MD
Tung-Hao Chang, MD
Chi-Yon Lin, MS
Yi-Chuan Wu, MS
Bi-Wen Su, MS
Kuan-Der Lee, MD, PhD
Pey-Jium Chang, PhD
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1118-9

Other articles of this Issue 11/2010

Annals of Surgical Oncology 11/2010 Go to the issue

Breast Oncology

Pathological Processing Techniques and Final Diagnosis of Breast Cancer Sentinel Lymph Nodes

Pancreatic Tumors

Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

Melanomas

Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

Translational Research and Biomarkers

Prognostic Significance of E-cadherin Expression and Peripheral Blood Micrometastasis in Gastric Carcinoma Patients

Colorectal Cancer

Absence of hMLH1 or hMSH2 Expression as a Stage-Dependent Prognostic Factor in Sporadic Colorectal Cancers

Reconstructive Oncology

Immediate Microvascular Breast Reconstruction After Neoadjuvant Chemotherapy: Complication Rates and Effect on Start of Adjuvant Treatment